Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
4.715
+0.165 (3.63%)
At close: Aug 22, 2025, 4:00 PM
4.715
0.00 (0.00%)
After-hours: Aug 22, 2025, 4:10 PM EDT

Acurx Pharmaceuticals Stock Forecast

ACXP's stock price has decreased by -89.92% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 3 analysts that cover Acurx Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $143.67, which forecasts a 2,947.08% increase in the stock price over the next year. The lowest target is $31 and the highest is $240.

Price Target: $143.67 (+2,947.08%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$31$143.67$160$240
Change+557.48%+2947.1%+3293.4%+4990.1%

Analyst Ratings

The average analyst rating for Acurx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingMar '25Apr '25May '25Jun '25Jul '25Aug '25
Strong Buy112223
Buy000000
Hold000000
Sell000000
Strong Sell000000
Total112223

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$8$31
Strong BuyMaintains$8$31+557.48%Aug 12, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$160
Strong BuyInitiates$160+3,293.43%May 15, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$240
Strong BuyReiterates$240+4,990.14%Mar 19, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$240
Strong BuyReiterates$240+4,990.14%Jan 13, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$240
Strong BuyReiterates$240+4,990.14%Jan 10, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
4.59M
Revenue Next Year
132.60K
from 4.59M
Decreased by -97.11%
EPS This Year
-0.51
from -17.45
EPS Next Year
-0.52
from -0.51
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
-----4.59M132.60K4.59M
Revenue Growth
-------97.11%3,361.54%
EPS
-14.86-29.87-22.36-23.01-17.45-0.51-0.52-0.53
EPS Growth
--------
Forward PE
--------
No. Analysts
-----555
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High14.2M409,50014.2M
Avg4.6M132,6004.6M
Lown/an/an/a

Revenue Growth

Revenue Growth20252026202720282029
High-
-91.1%
10,590.0%
Avg-
-97.1%
3,361.5%
Low---

EPS Forecast

EPS202520262027
High-0.47-0.41-0.37
Avg-0.51-0.52-0.53
Low-0.59-0.58-0.61

EPS Growth

EPS Growth202520262027
High---
Avg---
Low---
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.